Iqvia reported second-quarter revenue of $4.4 billion, up nearly 9% year over year, and adjusted diluted earnings per share of $3.15, up 12%. Management raised its 2026 outlook, including a 77-basis-point increase to the midpoint of its previous revenue guidance. Shares rose 14% on July 28.
Iqvia's leading position in outsourced clinical trials allows it to create sticky client relationships, further honing clinical and regulatory expertise.
The company's next-generation solutions could lose traction among clients or fail to gain traction with regulatory bodies.
|
Metric
|
IQV
|
ICLR
|
FTRE
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.37 | 15.38 | 133.30 |
Price/Book Value | 6.44 | 1.38 | 3.23 |
Price/Sales | 2.42 | 1.56 | 0.62 |
Price/Cash Flow | 15.70 | 13.54 | 31.72 |
|
Metric
|
IQV
|
ICLR
|
FTRE
|
|---|---|---|---|
Quick Ratio | 0.62 | 0.92 | 0.85 |
Current Ratio | 0.71 | 0.95 | 0.96 |
Interest Coverage | 2.99 | 1.53 | 0.08 |
|
Metric
|
IQV
|
ICLR
|
FTRE
|
|---|---|---|---|
Return on Assets (Normalized) | 7.22% | 3.91% | −0.58% |
Return on Equity (Normalized) | 34.41% | 6.87% | −2.83% |
Return on Invested Capital (Normalized) | 12.37% | 6.21% | 2.96% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|xP<<j!Pl | LOCK|$> | $220B | |||
| Danaher Corp
DHR
| LOCK|s$Pt$@?H | LOCK|sy | $143B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|wwqd<&Z | LOCK|#^< | $45B | |||
| Agilent Technologies Inc
A
| LOCK|&^<s$CLQ | LOCK|V$< | $42B | |||
| Waters Corp
WAT
| LOCK|ZfdV?FJ | LOCK|V>? | $41B | |||
| Illumina Inc
ILMN
| LOCK|lfScZN$ | LOCK|g^kH | $29B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|>BKp#MJ | LOCK|M^jFd | $29B | |||
| Labcorp Holdings Inc
LH
| LOCK|J&b$G#p | LOCK|sQl#M | $26B | |||
| Quest Diagnostics Inc
DGX
| LOCK|<Q?KJg^ | LOCK|^Hbt | $26B |
United States